You are in: eMedicine Specialties > Gastroenterology > Biliary Emphysematous CholecystitisArticle Last Updated: Jul 11, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Alan A Bloom, MD, Associate Clinical Professor of Medicine, Albert Einstein College of Medicine; Attending Physician, Department of Gastroenterology, Veterans Affairs Hospital, Bronx Alan A Bloom is a member of the following medical societies: American College of Physicians, American Gastroenterological Association, American Medical Association, American Society for Gastrointestinal Endoscopy, New York Academy of Medicine, and New York Academy of Sciences Coauthor(s): Prospere Remy, MD, Assistant Professor of Medicine, Albert Einstein College of Medicine; Attending Physician, Department of Internal Medicine, Bronx-Lebanon Hospital Center Editors: Burt Cagir, MD, FACS, Assistant Professor of Surgery, State University of New York, Upstate Medical Center; Consulting Staff, Director of Surgical Research, Robert Packer Hospital; Associate Program Director, Department of Surgery, Guthrie Clinic; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; BS Anand, MD, Department of Internal Medicine, Division of Gastroenterology, Professor, Baylor University College of Medicine; Alex J Mechaber, MD, FACP, Assistant Dean for Medical Curriculum, Associate Professor of Medicine, Division of General Internal Medicine, University of Miami Miller School of Medicine; Julian Katz, MD, Clinical Professor of Medicine, Drexel University College of Medicine; Consulting Staff, Department of Medicine, Section of Gastroenterology and Hepatology, Hospital of the Medical College of Pennsylvania Author and Editor Disclosure Synonyms and related keywords: emphysematous cholecystitis, acute cholecystitis, acute gaseous cholecystitis, clostridial cholecystitis, cholecystitis secondary to gas-forming organisms, acalculous cholecystitis, acute calculous cholecystitis, acute pneumocholecystitis, acute pneumopyocholecystitis, gallbladder infection, gallbladder wall infection, infection of the gallbladder wall, gallstones, arteriosclerosis INTRODUCTIONBackgroundEmphysematous cholecystitis is an acute infection of the gallbladder wall caused by gas-forming organisms. First described by Stoltz in 1901, it was thought to be a rare disorder. However, as a result of improved imaging techniques, it is now being described with increasing frequency. PathophysiologyFour pathogenetic factors are proposed in the development of emphysematous cholecystitis. Vascular compromise of the gallbladder In most cases, the cystic artery is the sole arterial supply of the gallbladder. Occlusion or stenosis results in compromised viability of the gallbladder. Arteriosclerosis is the usual causative abnormality, although the condition has been described after an embolic event. The evidence that vascular insufficiency is a root cause of emphysematous cholecystitis is circumstantial, that is, association with diabetes mellitus, greater incidence in males, high frequency of gangrene, and occurrence in older patients. However, exceptions exist for each of these. Gallstones Gallstones are observed in 28-80% of patients with emphysematous cholecystitis. Impaction of stones in the cystic duct leads to localized edema of the wall, which contributes to the vascular compromise of the gallbladder. Nevertheless, emphysematous cholecystitis in the presence of acalculous cholecystitis is well established. Indeed, the proportion of patients with acalculous cholecystitis in association with emphysematous cholecystitis exceeds that of patients with ordinary acute calculous cholecystitis. These observations raise doubt about the role of gallstones in the pathogenesis of emphysematous cholecystitis.1, 2 Impaired immune protection Diabetes mellitus is detected in 38-55% patients with emphysematous cholecystitis, and the mean age of patients is 59 years. Both metabolic abnormality and older age probably contribute to the increased risk of infection. Infection with gas-forming organisms Microorganisms commonly isolated are clostridial species, Escherichia coli, and Klebsiella species. Less frequently, enterococci and anaerobic streptococci are among the other organisms detected. While the intramural gas observed in patients with emphysematous cholecystitis seems to result from gas-forming bacteria, whether these bacteria represent the primary cause of the disorder or are secondary invaders remains unclear. Concomitant emphysematous cholecystitis and emphysematous pyelonephritis raise the possibility of septic seeding of the gallbladder wall. See related CME at New Guidelines Address Management of Common Bile Duct Stones. FrequencyUnited StatesEmphysematous cholecystitis occurs infrequently. Reports in the surgical literature indicate that emphysematous cholecystitis develops in approximately 1% of all cases of acute cholecystitis. Mortality/MorbidityOverall mortality rates vary from 15-25%. These rates are 5 times the operative mortality rates for nonemphysematous cholecystitis. In addition to the septic character of the disease, comorbidities attendant to advanced age and diabetes mellitus also add to the risk of mortality.2 RaceNo racial predilection has been described. SexUnlike other biliary tract disorders, emphysematous cholecystitis occurs more frequently in men; men comprise 65-70% of all patients with emphysematous cholecystitis.3, 2 AgeThe disease occurs more commonly in older patients. In one study, the mean age of 20 patients was 59 years, and, in another study, 59% of patients were aged 60 years or older. CLINICALHistoryThe typical patient is a man older than 60 years, often with type II diabetes mellitus. Otherwise, the clinical scenario does not differ significantly from that observed in acute calculous cholecystitis.
Physical
CausesSee Pathophysiology. DIFFERENTIALSCholecystitis
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Imipenem and cilastin (Primaxin) |
|---|---|
| Description | For treatment of infections caused by multiple organisms in which other agents do not have broad-spectrum coverage or are contraindicated because of potential for toxicity. Because emphysematous cholecystitis is characterized by necrosis, perforation, and a high mortality rate, higher doses are advisable. |
| Adult Dose | Base initial dose on the severity of infection and administer in equally divided doses 250-500 mg IV q6h; not to exceed 3-4 g/d 500-750 mg IM or intra-abdominally q12h |
| Pediatric Dose | <12 years: Not established >3 months: 15-25 mg/kg/dose IV q6h suggested Fully susceptible organisms: Not to exceed 2 g/d Infections with moderately susceptible organisms: Not to exceed 4 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with cyclosporine may increase adverse CNS effects of both agents; coadministration with ganciclovir may result in generalized seizures; effects may be prolonged by probenecid |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adjust dose in renal insufficiency; caution in children <12 y; monitor for development of pseudomembranous colitis |
| Drug Name | Piperacillin and tazobactam (Zosyn) |
|---|---|
| Description | Antipseudomonal penicillin plus beta-lactamase inhibitor. It inhibits biosynthesis of cell wall mucopeptide and is effective during the stage of active multiplication. |
| Adult Dose | 3.375 g IV q6h |
| Pediatric Dose | 75 mg/kg IV q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | May inactivate aminoglycosides; probenecid may increase penicillin levels; neuromuscular blockade if used with vecuronium; may produce false-positive results for glucose if Clinitest tab is used to test urine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy (this may be complicated by elevations in the transferases associated with emphysematous cholecystitis); use caution in patients diagnosed with hepatic disorders; perform urinalysis and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions; monitor for appearance of pseudomembranous enterocolitis |
| Drug Name | Ticarcillin and clavulanate (Timentin) |
|---|---|
| Description | Inhibits biosynthesis of cell wall mucopeptide and is effective during the stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive, gram-negative, and anaerobic organisms. |
| Adult Dose | 3.1 g IV q4-6h |
| Pediatric Dose | 75 mg/kg IV q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Tetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; the effects are synergistic when administered concurrently with aminoglycosides; probenecid may increase penicillin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during treatment; exercise caution in patients diagnosed with hepatic insufficiency; perform urinalysis and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions |
| Drug Name | Ampicillin and sulbactam (Unasyn) |
|---|---|
| Description | Drug combination of beta-lactamase inhibitor with ampicillin. Covers epidermal organisms, enteric flora, and anaerobic organisms. Not ideal for nosocomial pathogens. |
| Adult Dose | 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (2 g ampicillin plus 1 g sulbactam) IV/IM q6-8h; not to exceed 4 g/d sulbactam or 8 g/d ampicillin |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 100-200 mg/kg/d ampicillin (150-300 mg Unasyn) IV divided q6h >12 years: Administer as in adults; not to exceed 4 g/d sulbactam or 8 g/d ampicillin |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
| Drug Name | Gentamicin (Garamycin) |
|---|---|
| Description | Aminoglycoside antibiotic for gram-negative coverage. Used in combination with both an agent against gram-positive organisms and one that covers anaerobic organisms. Not the drug of choice. Consider if penicillins or other less toxic drugs are contraindicated, when clinically indicated, and in mixed infections caused by susceptible staphylococci and gram-negative organisms. Dosing regimens are numerous; adjust dose based on CrCl and changes in volume of distribution. May be administered IV/IM. |
| Adult Dose | Serious infections and normal renal function: 3 mg/kg/d IV q8h Loading dose and maintenance dose: 1-2.5 mg/kg IV and 1-1.5 mg/kg IV, respectively, q8h Extended dosing regimen for life-threatening infections: 5 mg/kg/d IV/IM q6-8h Follow each regimen by at least a trough level drawn after the third or fourth dose (0.5 h before dosing); may draw a peak level 0.5 h after 30-min infusion |
| Pediatric Dose | <5 years: 2.5 mg/kg per dose IV/IM q8h >5 years: 1.5-2.5 mg/kg per dose IV/IM q8h or 6-7.5 mg/kg/d divided q8h; not to exceed 300 mg/d; monitor as in adults |
| Contraindications | Documented hypersensitivity; non–dialysis-dependent renal insufficiency |
| Interactions | Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents, thus prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (requires regular monitoring) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Metronidazole (Flagyl) |
|---|---|
| Description | Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for Clostridium difficile enterocolitis). |
| Adult Dose | Loading dose: 15 mg/kg (1 g for 70-kg adult) IV over 1 h Maintenance dose: 6 h following loading dose, 7.5 mg/kg (500 mg for 70-kg adult) IV infused over 1 h q6-8h; not to exceed 4 g/d |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Cimetidine may increase toxicity of metronidazole; may increase effects of anticoagulants; may increase toxicity of lithium and phenytoin; disulfiramlike reaction may occur with orally ingested ethanol |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy; caution in women who are breastfeeding or in first trimester of pregnancy |
| Drug Name | Levofloxacin (Levaquin) |
|---|---|
| Description | For pseudomonal infections and infections caused by multi-drug–resistant gram-negative organisms. |
| Adult Dose | 500 mg PO qd for 7-14 d |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; reduces therapeutic effects of phenytoin; probenecid may increase serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, NSAIDs, oral hypoglycemics, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin with broad-spectrum gram-negative activity. Lower efficacy against gram-positive organisms. Higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins. |
| Adult Dose | Uncomplicated infections: 250 mg IM once; not to exceed 4 g Severe infections: 1-2 g IV qd or divided bid; not to exceed 4 g/d |
| Pediatric Dose | <7 days: Not established >7 days: 25-50 mg/kg/d IV/IM; not to exceed 125 mg/d Infants and children: 50-75 mg/kg/d IV/IM divided q12h; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal impairment; caution in women who are breastfeeding and in those allergic to penicillin |
| Drug Name | Ertapenem (Invanz) |
|---|---|
| Description | Bactericidal activity results from inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin-binding proteins. Stable against hydrolysis by a variety of beta-lactamases including penicillinases, cephalosporinases, and extended-spectrum beta-lactamases. Hydrolyzed by metallo-beta-lactamases. |
| Adult Dose | 1 g qd for 14 d if IV and 7 d if IM; infuse over 30 min if IV |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity to drug or amide-type anesthetics |
| Interactions | Probenecid may reduce renal clearance of ertapenem and increase half-life, but benefit is minimum and does not justify coadministration |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Pseudomembranous colitis may occur; seizures and CNS adverse reactions may occur; when using with lidocaine to administer intramuscularly, avoid inadvertent injection into blood vessel |
| Drug Name | Cefepime (Suprax) |
|---|---|
| Description | Fourth-generation cephalosporin. Gram-negative coverage comparable to ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). Cefepime is a zwitter ion; rapidly penetrates gram-negative cells. Best beta-lactam for IM administration. |
| Adult Dose | 1-2 g IV q12h for 5-10 d; pseudomonal infections require higher doses |
| Pediatric Dose | 50 mg/kg IV q8h; not to exceed 2g |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effects of cefepime; aminoglycosides increase the nephrotoxic potential of cefepime |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Dosage adjustments (adult adjustments) CrCl (mL/min) 80-50: 0.5-2 g q12-24h CrCl 50-10: 0.5-2 g/d CrCl <10: 0.25-0.5 g/d HD: As for CrCl <10, with an extra 0.25 g after HD During peritoneal dialysis: 1-2 g q48h High doses may cause CNS toxicity; prolonged use of cefepime may predispose patients to superinfection |
| Media file 1: Emphysematous cholecystitis. A 47-year-old man with diabetes who experienced abdominal pain. Computerized tomography scan shows gas within the wall of the gallbladder (horizontal arrow) as well as within the lumen of the gallbladder (vertical arrow). Radiograph courtesy of Helen Morehouse, MD. | |
![]() | View Full Size Image | Media type: CT |
| Media file 2: Emphysematous cholecystitis. A 61-year-old nondiabetic man with right upper quadrant abdominal pain, fever, and leukocytosis. Film shows the gallbladder with multiple stones. The wall of fundus is delineated by intramural gas. Extramural gas also appears to be present in the soft tissues over the superior aspect of the gallbladder. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 3: Emphysematous cholecystitis. A 78-year-old man with diabetes with minimal abdominal distress. The film shows an enlarged gallbladder with multiple stones. The wall of the gallbladder is outlined by intramural gas. | |
![]() | View Full Size Image | Media type: X-RAY |
Emphysematous Cholecystitis excerpt
Article Last Updated: Jul 11, 2008